Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

Mark Fleisher, Jan Marsal, Scott D. Lee, Laura E. Frado, Alyssa Parian, Burton I. Korelitz, Brian G. Feagan

Research output: Contribution to journalArticle

Abstract

Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalDigestive Diseases and Sciences
DOIs
StateAccepted/In press - Feb 26 2018

Fingerprint

Inflammatory Bowel Diseases
Pyoderma Gangrenosum
Erythema Nodosum
Joint Diseases
Uveitis
Ulcerative Colitis
Crohn Disease
Therapeutics
Sacroiliitis
Intestinal Diseases
Ankylosing Spondylitis
Arthralgia
Arthritis
vedolizumab
Monoclonal Antibodies

Keywords

  • Crohn’s disease
  • Extraintestinal manifestations
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. / Fleisher, Mark; Marsal, Jan; Lee, Scott D.; Frado, Laura E.; Parian, Alyssa; Korelitz, Burton I.; Feagan, Brian G.

In: Digestive Diseases and Sciences, 26.02.2018, p. 1-9.

Research output: Contribution to journalArticle

Fleisher, Mark ; Marsal, Jan ; Lee, Scott D. ; Frado, Laura E. ; Parian, Alyssa ; Korelitz, Burton I. ; Feagan, Brian G. / Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. In: Digestive Diseases and Sciences. 2018 ; pp. 1-9.
@article{88da2d7168d4434aba547613ec94da1c,
title = "Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease",
abstract = "Background: Approximately 15–20{\%} of ulcerative colitis patients and 20–40{\%} of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.",
keywords = "Crohn’s disease, Extraintestinal manifestations, Inflammatory bowel disease, Ulcerative colitis",
author = "Mark Fleisher and Jan Marsal and Lee, {Scott D.} and Frado, {Laura E.} and Alyssa Parian and Korelitz, {Burton I.} and Feagan, {Brian G.}",
year = "2018",
month = "2",
day = "26",
doi = "10.1007/s10620-018-4971-1",
language = "English (US)",
pages = "1--9",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",

}

TY - JOUR

T1 - Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease

AU - Fleisher, Mark

AU - Marsal, Jan

AU - Lee, Scott D.

AU - Frado, Laura E.

AU - Parian, Alyssa

AU - Korelitz, Burton I.

AU - Feagan, Brian G.

PY - 2018/2/26

Y1 - 2018/2/26

N2 - Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

AB - Background: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intestinal disease activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a gut-selective mechanism of action. Aims: This report evaluates whether vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism of action. Methods: We report 8 case studies of patients with various EIMs, including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy. Results: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing spondylitis/sacroiliitis but did not provide sustained benefit for the treatment of pyoderma gangrenosum in a patient with Crohn’s disease. Conclusions: These cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients with IBD.

KW - Crohn’s disease

KW - Extraintestinal manifestations

KW - Inflammatory bowel disease

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85042533542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042533542&partnerID=8YFLogxK

U2 - 10.1007/s10620-018-4971-1

DO - 10.1007/s10620-018-4971-1

M3 - Article

C2 - 29484571

AN - SCOPUS:85042533542

SP - 1

EP - 9

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

ER -